Show simple item record

dc.contributor.authorGenead, Mohamed A.
dc.contributor.authorMcAnany, J. Jason
dc.contributor.authorFishman, Gerald A.
dc.date.accessioned2013-11-19T19:50:42Z
dc.date.available2013-11-19T19:50:42Z
dc.date.issued2012-04
dc.identifier.bibliographicCitationGenead MA, McAnany JJ, Fishman GA. Topical dorzolamide for treatment of cystoid macular edema in patients with choroideremia. Retina. 2012 Apr;32(4):826-33. doi: 10.1097/IAE.0b013e3182215ae9en_US
dc.identifier.issn1539-2864
dc.identifier.urihttp://hdl.handle.net/10027/10548
dc.descriptionPost print version of article may differ from published version. The final publication is available at www.lww.com/; DOI:10.1097/IAE.0b013e3182215ae9en_US
dc.description.abstractPURPOSE: To determine the value of a topical carbonic anhydrase inhibitor on the macular thickness and function in choroideremia patients with cystoid macular edema. METHODS: : Two choroideremia patients with cystoid macular edema, observed by spectral-domain optical coherence tomography, were treated with a topical form of carbonic anhydrase inhibitor. Examinations performed before and during treatment included best-corrected visual acuity by using the Early Treatment Diabetic Retinopathy Study charts and contrast sensitivity measured with briefly presented grating targets and the Pelli-Robson letter contrast sensitivity chart, microperimetry, and spectral-domain optical coherence tomography. RESULTS: : The 2 choroideremia patients treated with dorzolamide 2% formulation had a noticeable reduction in macular thickness by spectral-domain optical coherence tomography. This reduction was found in both eyes after 2 months of treatment. After an additional 3 months of the same treatment regimen, a more noticeable reduction in macular thickness was observed. The two study patients had improvement of their visual acuity, in at least one eye, on Early Treatment Diabetic Retinopathy Study charts, but no clinically significant changes for the other measures of visual function. CONCLUSION: : The present study shows the potential efficacy of topical dorzolamide for treating choroideremia patients with cystoid macular edema.en_US
dc.description.sponsorshipSupported by funds from the Foundation Fighting Blindness, Owings Mills, Maryland; Grant Healthcare Foundation, Lake Forest, Illinois; NIH research grant EY019510 (JM); NIH core grant EYO1792; and an unrestricted departmental grant from Research to Prevent Blindnessen_US
dc.language.isoen_USen_US
dc.publisherLippincott, Williams & Wilkinsen_US
dc.subjectCystoid macular edemaen_US
dc.subjectChoroideremiaen_US
dc.subjectCarbonic anhydrase inhibitoren_US
dc.subjectSpectraldomain OCTen_US
dc.titleTopical Dorzolamide for Treatment of Cystoid Macular Edema in Patients with Choroideremiaen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record